Average Weight Loss on Ozempic from Clinical Trials
In the STEP 1 trial, adults with obesity (no diabetes) on semaglutide 2.4 mg weekly lost an average of 15% body weight over 68 weeks, compared to 2.4% on placebo.[1] The SUSTAIN FORTE trial showed 15.5% average loss at 40 weeks for type 2 diabetes patients.[1] Real-world data from a 2021 study of over 1,000 patients reported 10-15 lbs (4.5-6.8 kg) loss in the first 3 months, scaling to 20-30 lbs by 6 months.[2]
How Much Weight Loss by Timeframe
- First month: 2-5 lbs typical, as appetite suppression kicks in.
- 3 months: 10-20 lbs for many, per patient forums and a 2023 VA study of 11,000 users.[3]
- 6-12 months: Up to 25-35 lbs (11-16 kg), with 15-20% total body weight loss in responders; plateaus common after.[1][4]
Individual results vary by dose (0.25-2.4 mg), diet, exercise, and starting weight—higher BMI users often lose more initially.
Factors Affecting Weight Loss Results
Starting dose titration (from 0.25 mg) minimizes nausea, aiding adherence. Combining with calorie deficit and activity boosts outcomes: one trial added 5% more loss with lifestyle changes.[1] Women and those under 50 tend to lose faster; men or older adults slower.[2] About 20-30% of users lose under 5% body weight, often due to side effects or non-adherence.[4]
What If Weight Loss Stops or Rebounds?
Plateaus hit around 6 months for half of users; dose increase or cycling exercise helps some regain momentum.[3] Stopping Ozempic leads to 2/3 of weight returning within a year, per a 2022 Danish study of 14,000 patients—muscle loss during use contributes if protein intake is low.[5] Long-term maintenance requires ongoing use or switches like tirzepatide.
Patient Experiences and Real-World Reports
On Reddit (r/Ozempic) and forums, users report 1-2 lbs/week early on: "50 lbs in 6 months at 2.4 mg, effortless hunger control" vs. "Only 8 lbs in 4 months, constant nausea." A 2024 survey of 1,200 users found 70% lost 10+ lbs, but 15% gained due to compensatory eating post-loss.[6] Doctors note non-responders (10-20%) may need alternatives.
[1] NEJM: Semaglutide STEP Trials
[2] JAMA: Real-World Weight Loss with GLP-1s
[3] Annals of Internal Medicine: VA Ozempic Study
[4] Diabetes Care: Long-Term Outcomes
[5] Ugeskr Laeger: Weight Regain Post-Semaglutide
[6] Signos Survey 2024